These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20602263)

  • 1. Palonosetron for prevention of acute and delayed nausea and vomiting in non-small-cell lung carcinoma patients.
    Dong X; Huang J; Cao R; Liu L
    Med Oncol; 2011 Dec; 28(4):1425-9. PubMed ID: 20602263
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palonosetron versus ondansetron for prevention of chemotherapy-induced nausea and vomiting in paediatric patients with cancer receiving moderately or highly emetogenic chemotherapy: a randomised, phase 3, double-blind, double-dummy, non-inferiority study.
    Kovács G; Wachtel AE; Basharova EV; Spinelli T; Nicolas P; Kabickova E
    Lancet Oncol; 2016 Mar; 17(3):332-344. PubMed ID: 26795844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
    Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
    Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
    Rubenstein EB
    Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.
    Gralla R; Lichinitser M; Van Der Vegt S; Sleeboom H; Mezger J; Peschel C; Tonini G; Labianca R; Macciocchi A; Aapro M
    Ann Oncol; 2003 Oct; 14(10):1570-7. PubMed ID: 14504060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of palonosetron and dexamethasone with or without aprepitant to prevent carboplatin-induced nausea and vomiting in patients with advanced non-small-cell lung cancer.
    Kusagaya H; Inui N; Karayama M; Fujisawa T; Enomoto N; Kuroishi S; Nakamura Y; Matsuda H; Yokomura K; Koshimizu N; Toyoshima M; Imokawa S; Yamada T; Shirai T; Hayakawa H; Suda T
    Lung Cancer; 2015 Dec; 90(3):410-6. PubMed ID: 26791800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
    Balu S; Buchner D; Craver C; Gayle J
    Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: a phase 3 trial.
    Boccia R; Grunberg S; Franco-Gonzales E; Rubenstein E; Voisin D
    Support Care Cancer; 2013 May; 21(5):1453-60. PubMed ID: 23354552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palonosetron: in the prevention of nausea and vomiting.
    Yang LP; Scott LJ
    Drugs; 2009 Nov; 69(16):2257-78. PubMed ID: 19852528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
    Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
    Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL).
    Di Renzo N; Montanini A; Mannina D; Dondi A; Muci S; Mancuso S; De Paolis MR; Plati C; Stelitano C; Patti C; Olivieri A; Liardo E; Buda G; Cantaffa R; Federico M
    Support Care Cancer; 2011 Oct; 19(10):1505-10. PubMed ID: 20694798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy.
    Celio L; Agustoni F; Testa I; Dotti K; de Braud F
    Tumori; 2012; 98(3):279-86. PubMed ID: 22825501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase III, double-blind, randomized trial of palonosetron compared with ondansetron in preventing chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.
    Aapro MS; Grunberg SM; Manikhas GM; Olivares G; Suarez T; Tjulandin SA; Bertoli LF; Yunus F; Morrica B; Lordick F; Macciocchi A
    Ann Oncol; 2006 Sep; 17(9):1441-9. PubMed ID: 16766588
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of palonosetron as salvage treatment in the prevention of chemotherapy-induced nausea and vomiting in patients receiving low emetogenic chemotherapy (LEC).
    Hesketh PJ; Morrow G; Komorowski AW; Ahmed R; Cox D
    Support Care Cancer; 2012 Oct; 20(10):2633-7. PubMed ID: 22733373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of a single-day three-drug regimen of dexamethasone, palonosetron, and aprepitant for the prevention of acute and delayed nausea and vomiting caused by moderately emetogenic chemotherapy.
    Grunberg SM; Dugan M; Muss H; Wood M; Burdette-Radoux S; Weisberg T; Siebel M
    Support Care Cancer; 2009 May; 17(5):589-94. PubMed ID: 19037667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
    Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
    Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron.
    Eisenberg P; Figueroa-Vadillo J; Zamora R; Charu V; Hajdenberg J; Cartmell A; Macciocchi A; Grunberg S;
    Cancer; 2003 Dec; 98(11):2473-82. PubMed ID: 14635083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice.
    Hatoum HT; Lin SJ; Buchner D; Cox D
    Support Care Cancer; 2012 May; 20(5):941-9. PubMed ID: 21533811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
    Gamble M; Carroll E; Wright GC; Glode AE
    J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study.
    Seol YM; Kim HJ; Choi YJ; Lee EM; Kim YS; Oh SY; Koh SJ; Baek JH; Lee WS; Joo YD; Lee HG; Yun EY; Chung JS
    Support Care Cancer; 2016 Feb; 24(2):945-952. PubMed ID: 26265119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.